A large majority of patients with Fragile X Syndrome reported that CBD improved some of their symptoms and “made a positive difference overall” in a new study.
The study was published in the journal Genes as well as on the website for the U.S. National Library of Medicine, and is titled Parent and Caregiver Perspectives towards Cannabidiol as a Treatment for Fragile X Syndrome. It was conducted by researchers at Icahn School of Medicine in New York and the National Fragile X Foundation in Virginia.
“Cannabidiol (CBD) is a non-intoxicating chemical in cannabis plants that is being investigated as a candidate for treatment in Fragile X Syndrome (FXS), a leading known cause of inherited intellectual developmental disability”, states the study’s abstract. “Studies have shown that CBD can reduce symptoms such as anxiety, social avoidance, hyperactivity, aggression, and sleep problems.”
According to researchers “this is a qualitative study that utilized a voluntary-anonymous survey that consisted of questions regarding demographics, medical information, the form, type, brand, dose, and frequency of CBD use, the rationale for use, the perception of effects, side effects, and costs.”
The full survey contained a total of 34 questions, including multiple-choice, Likert-scale, and optional free-response questions.
“This research revealed that there are a wide range of types, brands, and doses of CBD being administered to individuals with FXS by their parents and caregivers”, the study states. “There were many reasons why CBD was chosen, the most common ones being that respondents had heard positive things about CBD from members of the community, the perception that CBD had fewer side effects than other medications, and because respondents felt that CBD was a more natural substance.”
Researchers found that “Most of the parents and caregivers who responded agreed that CBD improved some of the symptoms of FXS and made a positive difference overall.”
They conclude that “CBD has the therapeutic potential to help relieve some FXS symptoms”, noting that “Future research is necessary to understand the benefits of CBD in FXS.”
Below is the study’s full abstract.
Abstract
Cannabidiol (CBD) is a non-intoxicating chemical in cannabis plants that is being investigated as a candidate for treatment in Fragile X Syndrome (FXS), a leading known cause of inherited intellectual developmental disability. Studies have shown that CBD can reduce symptoms such as anxiety, social avoidance, hyperactivity, aggression, and sleep problems. This is a qualitative study that utilized a voluntary-anonymous survey that consisted of questions regarding demographics, medical information, the form, type, brand, dose, and frequency of CBD use, the rationale for use, the perception of effects, side effects, and costs. The full survey contained a total of 34 questions, including multiple-choice, Likert-scale, and optional free-response questions. This research revealed that there are a wide range of types, brands, and doses of CBD being administered to individuals with FXS by their parents and caregivers. There were many reasons why CBD was chosen, the most common ones being that respondents had heard positive things about CBD from members of the community, the perception that CBD had fewer side effects than other medications, and because respondents felt that CBD was a more natural substance. Most of the parents and caregivers who responded agreed that CBD improved some of the symptoms of FXS and made a positive difference overall. CBD has the therapeutic potential to help relieve some FXS symptoms. Future research is necessary to understand the benefits of CBD in FXS.
